<DOC>
	<DOCNO>NCT02888756</DOCNO>
	<brief_summary>iHIVARNA-01 novel therapeutic vaccine treatment HIV-1-infected patient base vivo modification DCs . It consist HIVACAT-TriMix : mRNA encode mixture APC activation molecule ( CD40L , constitutively active variant TLR4 CD70 ) HIV target antigen contain HIVACAT administer intranodal route . iHIVARNA-01 aim achieve 'functional cure ' HIV infection , i.e . control viral replication absence anti-retroviral therapy .</brief_summary>
	<brief_title>iHIVARNA Clinical Trial HIV Infected Individuals</brief_title>
	<detailed_description>Objective : To evaluate safety immunogenicity iHIVARNA-01 new therapeutic vaccine HIV infect patient . Study design duration : Phase IIa , multicentre double-blind placebo control intervention study . Each patient follow 30 week . The study duration 38 week inclusion first patient . Sites : Erasmus MC , Rotterdam The Netherlands ( sponsor ) , Hospital Clínic de Barcelona Institut de Recerca de la Sida - Caixa , Barcelona , Spain , Instituut voor Tropische Geneeskunde Antwerp , Belgium Vrije Universiteit Brussel/UZ Brussel , Belgium Study population : Chronically HIV-1- infected patient stable cART plasma viral load ( pVL ) ≤ 50 copies/ml stable CD4+ T-cell count ≥ 450/μl , age 18 year . Sample size : recruitment screening , 70 patient include randomized one study-arms . Intervention : One group ( n=40 ) receive HIVACAT-TriMix ( 300 microgram TriMix + 900 microgram HIVACAT ) vaccine intranodally three occasion two-week interval . One control group ( n=15 ) receive TriMix ( 300 microgram TriMix ) one group ( n=15 ) receive saline intranodally three occasion two-week interval . Two week last vaccination cART treatment interrupt . If plasma virus detectable , cART re-initiated twelve week treatment interruption . cART always re-initiated medical reason , judge clinical investigator .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . ≥ 18 year age ; 2 . Voluntarily sign informed consent ; 3 . Proven HIV1 infection ( documented antibody HIV1 detectable plasma HIV1 RNA initiation therapy ) ; 4 . On stable treatment cART regimen ( antiretroviral therapy consist least three registered antiretroviral agent ) least 3 year ; 5 . Nadir CD4+ ≥ 350 cells/μl ( 2 occasional determination ≤ 350 cells/μl allow ) ; 6 . Current CD4+ cell count ≥ 450 cells/μl ; 7 . HIVRNA 50 copies/mL last 6 month prior randomization , least two measurement ( occasional call 'blips ' ≤ 500 copies/mL permit ) ; 8 . If sexually active , willing use reliable method reduce risk transmission sexual partner treatment interruption ( include PrEP ) . 1 . For heterosexually active female , use effective method contraception partner ( combined oral contraceptive pill ; injectable implanted contraceptive ; IUD/IUS ; consistent record condom ; physiological anatomical sterility ( self partner ) 14 day prior first vaccination 4 month last vaccination . For heterosexually active male , use effective method contraception partner first day vaccination 4 month last vaccination . 1 . Treatment noncART regimen prior cART regimen ; 2 . Previous failure antiretroviral and/or mutation confer genotypic resistance antiretroviral therapy ; 3 . Nonsubtype B HIV infection ; 4 . Active Hepatitis B virus and/or Hepatitis C virus coinfection ; 5 . History CDC class C event ( see appendix A ) ; 6 . Pregnant female ( screen positive pregnancy test ) , lactate intend become pregnant study ; 7 . Active malignancy ≤ 30 day ( extended period clinical assessment investigator ) prior screen ; 8 . Active infection fever ( 38°C ) ≤ 10 day screen and/or first vaccination ; 9 . Therapy immunomodulatory agent ( e.g . systemic corticosteroid ) , include cytokine ( e.g . IL2 ) , immunoglobulins and/or cytostatic chemotherapy ≤ 90 day prior screen . This include seasonal influenza , hepatitis B and/or travel relate vaccine ; 10 . Congenital , acquire induced coagulation disorder , thrombocytopenia ( thrombocytes &lt; 150x109/L ) and/or current use anticoagulant medication ( e.g . coumarins , inhibitor Xa ) ; Usage NSAIDs ( include acetylsalicylic acid ) allow , however advise interrupt therapy 10 day ahead vaccination ; 11 . Usage investigational drug ≤ 90 day prior study entry ; 12 . An employee investigator study site , direct involvement propose study study direction investigator study site , family member employee investigator Any condition , , opinion investigator , may interfere evaluation study objective</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>mRNA</keyword>
	<keyword>Lentivirus infection</keyword>
	<keyword>Virus disease</keyword>
	<keyword>Sexually transmit disease</keyword>
	<keyword>Immunodeficiency syndrome</keyword>
</DOC>